RecruitingPhase 2NCT04698252

Local Therapy for ER/PR-positive Oligometastatic Breast Cancer

Local Therapy for Hormone Receptor-positive Oligometastatic Breast Cancer - a Phase II Randomized Trial

Sponsor

Instituto do Cancer do Estado de São Paulo

Enrollment

74 participants

Start Date

Apr 1, 2021

Study Type

INTERVENTIONAL

Conditions

Breast Cancer

Summary

Randomized phase 2 trial to evaluate the efficacy of local therapy for oligometastasis from ER/PR-positive breast cancer. The study hypothesis is that local therapy in addition to systemic therapy improves progression-free survival in comparison with systemic therapy alone.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is exploring whether using targeted local treatments — like surgery or radiation — on a small number of metastatic tumors can improve outcomes in women with ER/PR-positive (hormone receptor-positive) breast cancer that has spread to only a few sites in the body (called oligometastatic disease). **You may be eligible if...** - You are female, 18 or older - You have hormone receptor-positive (ER/PR+), HER2-negative breast cancer - You have a small number of metastases (1-4 spots) in bone, lung, liver, or certain lymph nodes - Your metastatic sites can be treated with surgery, radiation, or similar focused therapies **You may NOT be eligible if...** - You have HER2-positive breast cancer - You have more than 4 metastatic sites - You have widespread or uncontrolled metastatic disease - Your cancer has spread to the brain Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.